Clinical case of a patient undergoing radium-223 treatment following treatment with abiraterone acetate and enzalutamide
Objective: Over the last decade, significant advances have been made in the development of therapies for patients with metastatic castration-resistant prostate cancer. Abiraterone and enzalutamide were approved as treatments based on data supporting improved overall survival compared to placebo. Rad...
Збережено в:
| Опубліковано в: : | Experimental Oncology |
|---|---|
| Дата: | 2018 |
| Автори: | , , , , |
| Формат: | Стаття |
| Мова: | Англійська |
| Опубліковано: |
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
2018
|
| Теми: | |
| Онлайн доступ: | https://nasplib.isofts.kiev.ua/handle/123456789/145592 |
| Теги: |
Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|
| Назва журналу: | Digital Library of Periodicals of National Academy of Sciences of Ukraine |
| Цитувати: | Clinical case of a patient undergoing radium-223 treatment following treatment with abiraterone acetate and enzalutamide / M.E. Jiménez Romero, S. Díez Farto, J.C. Navarro Serrato, E. Canelón Castillo, I. Revelo Cadena // Experimental Oncology. — 2018 — Т. 40, № 2. — С. 144–148. — Бібліогр.: 13 назв. — англ. |
Репозитарії
Digital Library of Periodicals of National Academy of Sciences of Ukraine| _version_ | 1862552837113774080 |
|---|---|
| author | Jiménez Romero, M.E. Díez Farto, S. Navarro Serrato, J.C. Canelón Castillo, E. Revelo Cadena, I. |
| author_facet | Jiménez Romero, M.E. Díez Farto, S. Navarro Serrato, J.C. Canelón Castillo, E. Revelo Cadena, I. |
| citation_txt | Clinical case of a patient undergoing radium-223 treatment following treatment with abiraterone acetate and enzalutamide / M.E. Jiménez Romero, S. Díez Farto, J.C. Navarro Serrato, E. Canelón Castillo, I. Revelo Cadena // Experimental Oncology. — 2018 — Т. 40, № 2. — С. 144–148. — Бібліогр.: 13 назв. — англ. |
| collection | DSpace DC |
| container_title | Experimental Oncology |
| description | Objective: Over the last decade, significant advances have been made in the development of therapies for patients with metastatic castration-resistant prostate cancer. Abiraterone and enzalutamide were approved as treatments based on data supporting improved overall survival compared to placebo. Radium-223 became the first approved radiopharmaceutical which decreased skeletal-related events, palliated pain, and showed improved overall survival in symptomatic patients with castration-resistant prostate cancer and bone metastasis only. Materials and Methods: We present the case of an eighty-two year old man with metastatic castration-resistant prostate cancer who was treated with sequential therapy (abiraterone — enzalutamide — radium-223). The sequencing and treatment used for our patient was viable because of his clinical characteristics, which have allowed for longer survival time with an acceptable quality of life. These actions must be agreed on by the Multidisciplinary Tumour Board, in order to optimize the use of available courses of treatment. Results: The treatment of these patients is changing rapidly, but many questions remain regarding the optimal sequencing of the available drugs. Sequential or concomitant use of the next generation hormonal agents — abiraterone and enzalutamide — cannot currently be recommended. Data regarding the safety of concomitant abiraterone, enzalutamide or denosumab with radium-223 is reassuring and timely. However, we cannot advocate the general use of combined radium-223 therapy at this time, irrespective of prior therapy. Conclusion: A better understanding of active mechanisms, the genetic characteristics of each metastatic castration-resistant prostate cancer and the development of new prognostic and predictive biomarkers will help determine sequencing or different combination treatments for each individual patient. Key Words: castration-resistant prostate cancer, treatment sequence, abiraterone acetate, enzalutamide, radiopharmaceutic.
|
| first_indexed | 2025-11-25T21:04:10Z |
| format | Article |
| fulltext | |
| id | nasplib_isofts_kiev_ua-123456789-145592 |
| institution | Digital Library of Periodicals of National Academy of Sciences of Ukraine |
| issn | 1812-9269 |
| language | English |
| last_indexed | 2025-11-25T21:04:10Z |
| publishDate | 2018 |
| publisher | Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України |
| record_format | dspace |
| spelling | Jiménez Romero, M.E. Díez Farto, S. Navarro Serrato, J.C. Canelón Castillo, E. Revelo Cadena, I. 2019-01-24T09:57:18Z 2019-01-24T09:57:18Z 2018 Clinical case of a patient undergoing radium-223 treatment following treatment with abiraterone acetate and enzalutamide / M.E. Jiménez Romero, S. Díez Farto, J.C. Navarro Serrato, E. Canelón Castillo, I. Revelo Cadena // Experimental Oncology. — 2018 — Т. 40, № 2. — С. 144–148. — Бібліогр.: 13 назв. — англ. 1812-9269 https://nasplib.isofts.kiev.ua/handle/123456789/145592 Objective: Over the last decade, significant advances have been made in the development of therapies for patients with metastatic castration-resistant prostate cancer. Abiraterone and enzalutamide were approved as treatments based on data supporting improved overall survival compared to placebo. Radium-223 became the first approved radiopharmaceutical which decreased skeletal-related events, palliated pain, and showed improved overall survival in symptomatic patients with castration-resistant prostate cancer and bone metastasis only. Materials and Methods: We present the case of an eighty-two year old man with metastatic castration-resistant prostate cancer who was treated with sequential therapy (abiraterone — enzalutamide — radium-223). The sequencing and treatment used for our patient was viable because of his clinical characteristics, which have allowed for longer survival time with an acceptable quality of life. These actions must be agreed on by the Multidisciplinary Tumour Board, in order to optimize the use of available courses of treatment. Results: The treatment of these patients is changing rapidly, but many questions remain regarding the optimal sequencing of the available drugs. Sequential or concomitant use of the next generation hormonal agents — abiraterone and enzalutamide — cannot currently be recommended. Data regarding the safety of concomitant abiraterone, enzalutamide or denosumab with radium-223 is reassuring and timely. However, we cannot advocate the general use of combined radium-223 therapy at this time, irrespective of prior therapy. Conclusion: A better understanding of active mechanisms, the genetic characteristics of each metastatic castration-resistant prostate cancer and the development of new prognostic and predictive biomarkers will help determine sequencing or different combination treatments for each individual patient. Key Words: castration-resistant prostate cancer, treatment sequence, abiraterone acetate, enzalutamide, radiopharmaceutic. en Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України Experimental Oncology Case report Clinical case of a patient undergoing radium-223 treatment following treatment with abiraterone acetate and enzalutamide Article published earlier |
| spellingShingle | Clinical case of a patient undergoing radium-223 treatment following treatment with abiraterone acetate and enzalutamide Jiménez Romero, M.E. Díez Farto, S. Navarro Serrato, J.C. Canelón Castillo, E. Revelo Cadena, I. Case report |
| title | Clinical case of a patient undergoing radium-223 treatment following treatment with abiraterone acetate and enzalutamide |
| title_full | Clinical case of a patient undergoing radium-223 treatment following treatment with abiraterone acetate and enzalutamide |
| title_fullStr | Clinical case of a patient undergoing radium-223 treatment following treatment with abiraterone acetate and enzalutamide |
| title_full_unstemmed | Clinical case of a patient undergoing radium-223 treatment following treatment with abiraterone acetate and enzalutamide |
| title_short | Clinical case of a patient undergoing radium-223 treatment following treatment with abiraterone acetate and enzalutamide |
| title_sort | clinical case of a patient undergoing radium-223 treatment following treatment with abiraterone acetate and enzalutamide |
| topic | Case report |
| topic_facet | Case report |
| url | https://nasplib.isofts.kiev.ua/handle/123456789/145592 |
| work_keys_str_mv | AT jimenezromerome clinicalcaseofapatientundergoingradium223treatmentfollowingtreatmentwithabirateroneacetateandenzalutamide AT diezfartos clinicalcaseofapatientundergoingradium223treatmentfollowingtreatmentwithabirateroneacetateandenzalutamide AT navarroserratojc clinicalcaseofapatientundergoingradium223treatmentfollowingtreatmentwithabirateroneacetateandenzalutamide AT caneloncastilloe clinicalcaseofapatientundergoingradium223treatmentfollowingtreatmentwithabirateroneacetateandenzalutamide AT revelocadenai clinicalcaseofapatientundergoingradium223treatmentfollowingtreatmentwithabirateroneacetateandenzalutamide |